A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants.
Variants resistant to compounds specifically targeting HCV are observed in clinical trials. A multi-variant viral dynamic model was developed to quantify the evolution and in vivo fitness of variants in subjects dosed with monotherapy of an HCV protease inhibitor, telaprevir. Variant fitness was estimated using a model in which variants were selected by competition for shared limited replication space. Fitness was represented in the absence of telaprevir by different variant production rate constants and in the presence of telaprevir by additional antiviral blockage by telaprevir. Model parameters, including rate constants for viral production, clearance, and effective telaprevir concentration, were estimated from 1) plasma HCV RNA levels of subjects before, during, and after dosing, 2) post-dosing prevalence of plasma variants from subjects, and 3) sensitivity of variants to telaprevir in the HCV replicon. The model provided a good fit to plasma HCV RNA levels observed both during and after telaprevir dosing, as well as to variant prevalence observed after telaprevir dosing. After an initial sharp decline in HCV RNA levels during dosing with telaprevir, HCV RNA levels increased in some subjects. The model predicted this increase to be caused by pre-existing variants with sufficient fitness to expand once available replication space increased due to rapid clearance of wild-type (WT) virus. The average replicative fitness estimates in the absence of telaprevir ranged from 1% to 68% of WT fitness. Compared to the relative fitness method, the in vivo estimates from the viral dynamic model corresponded more closely to in vitro replicon data, as well as to qualitative behaviors observed in both on-dosing and long-term post-dosing clinical data. The modeling fitness estimates were robust in sensitivity analyses in which the restoration dynamics of replication space and assumptions of HCV mutation rates were varied.
Adiwijaya
Bambang S
BS
Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, United States of America. bambang_adiwijaya@vrtx.com
Herrmann
Eva
E
Hare
Brian
B
Kieffer
Tara
T
Lin
Chao
C
Kwong
Ann D
AD
Garg
Varun
V
Randle
John C R
JC
Sarrazin
Christoph
C
Zeuzem
Stefan
S
Caron
Paul R
PR
D003198:Computer Simulation; D024882:Drug Resistance, Viral / Q000235:genetics*; D019143:Evolution, Molecular; D056084:Genetic Fitness; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics*; D006526:Hepatitis C / Q000821:virology; D006801:Humans; D008954:Models, Biological; D015999:Multivariate Analysis; D009154:Mutation; D009842:Oligopeptides / Q000494:pharmacology*; D011480:Protease Inhibitors / Q000494:pharmacology*; D012367:RNA, Viral; D019562:Viral Load
D009842:Oligopeptides; D011480:Protease Inhibitors; D012367:RNA, Viral; C486464:telaprevir